HUE049931T2 - Nukleinsav, amely kapcsolva van trivalens glikokonjugátumhoz - Google Patents
Nukleinsav, amely kapcsolva van trivalens glikokonjugátumhozInfo
- Publication number
- HUE049931T2 HUE049931T2 HUE17715730A HUE17715730A HUE049931T2 HU E049931 T2 HUE049931 T2 HU E049931T2 HU E17715730 A HUE17715730 A HU E17715730A HU E17715730 A HUE17715730 A HU E17715730A HU E049931 T2 HUE049931 T2 HU E049931T2
- Authority
- HU
- Hungary
- Prior art keywords
- glycoconjugate
- trivalent
- nucleic acid
- acid linked
- linked
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163939.8A EP3228326A1 (en) | 2016-04-05 | 2016-04-05 | Nucleic acid linked to a trivalent glycoconjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049931T2 true HUE049931T2 (hu) | 2020-11-30 |
Family
ID=55697082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17715730A HUE049931T2 (hu) | 2016-04-05 | 2017-04-05 | Nukleinsav, amely kapcsolva van trivalens glikokonjugátumhoz |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10913945B2 (enExample) |
| EP (3) | EP3228326A1 (enExample) |
| JP (1) | JP7120925B2 (enExample) |
| CN (2) | CN116036117A (enExample) |
| AU (1) | AU2017245687B2 (enExample) |
| CA (1) | CA3019981A1 (enExample) |
| DK (1) | DK3439703T3 (enExample) |
| ES (1) | ES2805026T3 (enExample) |
| HU (1) | HUE049931T2 (enExample) |
| PL (1) | PL3439703T3 (enExample) |
| WO (1) | WO2017174657A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45478A (fr) * | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| EP3385272A1 (en) * | 2017-04-05 | 2018-10-10 | Silence Therapeutics GmbH | Further novel oligonucleotide-ligand conjugates |
| RS63887B1 (sr) | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Inhibicija tmprss6 posredovana rnk interferencijom |
| EP3483269A1 (en) | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| WO2018185252A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Nucleic acid conjugates |
| CA3056179A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| CN110520531A (zh) | 2017-04-05 | 2019-11-29 | 赛伦斯治疗有限责任公司 | 产品和组合物 |
| EP3550022A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions |
| WO2019092282A1 (en) | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| CA3081910A1 (en) * | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages |
| EP3483270A1 (en) | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| FI3710586T3 (fi) | 2017-11-13 | 2023-03-02 | Nukleiinihappoja LPA:n ekspression inhiboimiseksi solussa | |
| EP3549610A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Nucleic acid conjugates |
| EP3775207A1 (en) | 2018-04-05 | 2021-02-17 | Silence Therapeutics GmbH | Sirnas with vinylphosphonate at the 5' end of the antisense strand |
| EP3550021A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions for inhibiting expression of a target gene |
| EP3598995A1 (en) | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| WO2020099476A1 (en) * | 2018-11-13 | 2020-05-22 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| EP3730617A1 (en) | 2019-04-26 | 2020-10-28 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of c3 in a cell |
| WO2020104669A1 (en) | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| MX2021006210A (es) | 2018-11-26 | 2021-08-19 | Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. |
| US20220243202A1 (en) | 2019-05-07 | 2022-08-04 | Universität Bern | Nucleic acids for inhibiting expression of pros1 in a cell |
| CN114981430A (zh) * | 2019-08-27 | 2022-08-30 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中的c3表达的核酸 |
| KR20220058578A (ko) | 2019-09-03 | 2022-05-09 | 아크투루스 쎄라퓨틱스, 인크. | 치료 활성 접합체의 아시알로당단백질 수용체 매개 전달 |
| IL292391A (en) * | 2019-10-24 | 2022-06-01 | Genevant Sciences Gmbh | Bracelets and methods for treating acromegaly |
| US20240229041A2 (en) | 2020-05-27 | 2024-07-11 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Nucleic acids for inhibiting expression of cnnm4 in a cell |
| WO2022096424A1 (en) | 2020-11-04 | 2022-05-12 | Universität Bern | Nucleic acids for inhibiting expression of pros1 in a cell |
| JP2023547512A (ja) | 2020-11-04 | 2023-11-10 | ウニベルジテート ベルン | 細胞におけるｐｒｏｓ１の発現を阻害するための核酸 |
| WO2022184852A1 (en) | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| WO2022223557A1 (en) | 2021-04-20 | 2022-10-27 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of xdh in a cell |
| AU2022265493A1 (en) | 2021-04-27 | 2023-09-21 | Silence Therapeutics Gmbh | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders |
| CN118234861A (zh) | 2021-09-02 | 2024-06-21 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中的补体因子b(cfb)表达的核酸 |
| US20240271141A1 (en) * | 2021-11-29 | 2024-08-15 | Shanghai Argo Biopharmaceutical Co., Ltd. | Composition and method for inhibiting expression of hepatitis b virus (hbv)protein |
| WO2023208106A1 (zh) * | 2022-04-29 | 2023-11-02 | 石药集团中奇制药技术（石家庄）有限公司 | 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| WO2024126687A1 (en) | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| CN120981247A (zh) | 2023-03-27 | 2025-11-18 | 赛伦斯治疗有限责任公司 | 用于干细胞移植的化合物和组合物 |
| CN116444589B (zh) * | 2023-06-15 | 2023-09-19 | 北京悦康科创医药科技股份有限公司 | 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法 |
| GB202311334D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311324D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025021831A1 (en) | 2023-07-24 | 2025-01-30 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025132845A1 (en) | 2023-12-21 | 2025-06-26 | Silence Therapeutics Gmbh | Galnac phosphoramidites and their uses |
| WO2025162939A1 (en) | 2024-01-29 | 2025-08-07 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of gpr146 in a cell |
| WO2025163186A1 (en) | 2024-02-01 | 2025-08-07 | Silence Therapeutics Gmbh | Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell |
| WO2025169133A1 (en) | 2024-02-09 | 2025-08-14 | Astrazeneca Ab | Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| DK0618925T4 (da) | 1991-12-24 | 2012-07-09 | Isis Pharmaceuticals Inc | Antisense-oligonukleotider |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| EP1071753A2 (en) | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| RU2015119411A (ru) * | 2012-11-15 | 2017-01-10 | Рош Инновейшен Сентер Копенгаген А/С | Конъюгаты антисмысловых соединений, направленные на аполипопротеин в |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| EP3137605B1 (en) * | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| SG11201702877TA (en) * | 2014-10-10 | 2017-05-30 | Hoffmann La Roche | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
-
2016
- 2016-04-05 EP EP16163939.8A patent/EP3228326A1/en not_active Ceased
-
2017
- 2017-04-05 EP EP20171464.9A patent/EP3744350A1/en active Pending
- 2017-04-05 EP EP17715730.2A patent/EP3439703B1/en active Active
- 2017-04-05 DK DK17715730.2T patent/DK3439703T3/da active
- 2017-04-05 PL PL17715730T patent/PL3439703T3/pl unknown
- 2017-04-05 US US16/091,503 patent/US10913945B2/en active Active
- 2017-04-05 ES ES17715730T patent/ES2805026T3/es active Active
- 2017-04-05 CA CA3019981A patent/CA3019981A1/en active Pending
- 2017-04-05 CN CN202211456959.7A patent/CN116036117A/zh active Pending
- 2017-04-05 CN CN201780035060.9A patent/CN109562188B/zh active Active
- 2017-04-05 HU HUE17715730A patent/HUE049931T2/hu unknown
- 2017-04-05 WO PCT/EP2017/058112 patent/WO2017174657A1/en not_active Ceased
- 2017-04-05 AU AU2017245687A patent/AU2017245687B2/en active Active
- 2017-04-05 JP JP2018552707A patent/JP7120925B2/ja active Active
-
2020
- 2020-11-25 US US17/104,502 patent/US11912993B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3439703T3 (pl) | 2020-10-19 |
| AU2017245687B2 (en) | 2023-03-09 |
| EP3439703B1 (en) | 2020-04-29 |
| WO2017174657A1 (en) | 2017-10-12 |
| CN109562188B (zh) | 2022-12-06 |
| US20190119676A1 (en) | 2019-04-25 |
| JP2019510793A (ja) | 2019-04-18 |
| EP3744350A1 (en) | 2020-12-02 |
| EP3439703A1 (en) | 2019-02-13 |
| US20210079397A1 (en) | 2021-03-18 |
| ES2805026T3 (es) | 2021-02-10 |
| CN116036117A (zh) | 2023-05-02 |
| CA3019981A1 (en) | 2017-10-12 |
| US10913945B2 (en) | 2021-02-09 |
| AU2017245687A1 (en) | 2018-10-25 |
| EP3228326A1 (en) | 2017-10-11 |
| DK3439703T3 (da) | 2020-06-29 |
| JP7120925B2 (ja) | 2022-08-17 |
| CN109562188A (zh) | 2019-04-02 |
| US11912993B2 (en) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3439703T3 (pl) | Kwas nukleinowy połączony z trójwartościowym glikokoniugatem | |
| IL256499A (en) | Antibodies to CD40 | |
| SG11201610168YA (en) | Nucleic acid synthesis techniques | |
| IL254539A0 (en) | Biosensor | |
| GB201507119D0 (en) | Nucleic Acid Construct | |
| GB201507115D0 (en) | Nucleic Acid Construct | |
| PT3041507T (pt) | Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis | |
| GB201507111D0 (en) | Nucleic acid construct | |
| GB201507104D0 (en) | Nucleic acid construct | |
| GB201507108D0 (en) | Nucleic acid construct | |
| SI3094731T1 (sl) | S saharidom spremenjene molekule nukleinske kisline | |
| GB201405226D0 (en) | Nucleic acid preparation method | |
| GB201604376D0 (en) | Improvements to a propellar | |
| GB201517126D0 (en) | Structural connector | |
| SG11201507104WA (en) | Novel nucleic acid molecules | |
| GB201519542D0 (en) | Improvements relating to bend restrictors | |
| GB2539972B (en) | A connector | |
| ZA201802761B (en) | Process to produce a bio-product | |
| PL3371473T3 (pl) | Usprawnienia sprzęgła | |
| PL3311688T3 (pl) | Człon żeński dla zapięcia rzepowego | |
| GB2542153B (en) | A connector | |
| GB2557408B (en) | Improvements to a clock | |
| GB201616052D0 (en) | Improvements to cycles | |
| GB201500270D0 (en) | Enhancement to a mechanical lock | |
| GB201500226D0 (en) | Enhancement to a mechanical lock |